An estimated 80% of patients with systemic sclerosis (SSc) have pulmonary involvement, with interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) being the most common of these lung manifestations. In fact, both these conditions have been identified as the leading causes of SSc-related mortality.
In this episode of the European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress series, Toby Maher, MD, a professor of medicine and a pulmonologist, describes the increased prevalence of lung involvement in scleroderma and the need for routine screening among these patients.
Toby Maher, MD, is a professor of medicine and director of ILD at Keck School of Medicine, University of Southern California (USC), Los Angeles.
Dr Maher has spent the last 18 years specializing in the management of all forms of pulmonary fibrosis and orphan ILDs. He previously ran the ILD unit at Royal Brompton Hospital. Since June 2020, he has been the director of ILD at Keck Medicine of USC. He remains a professor of ILD at Imperial College, London, and is a British Lung Foundation professor of respiratory medicine.
Dr Maher’s research interests include biomarker discovery, the lung microbiome and host immune response in the pathogenesis of idiopathic pulmonary fibrosis (IPF), and clinical trials in ILD. He has been involved in more than 50 trials in fibrotic lung disease from phase 1b through to phase 4 and including those assessing IPF, scleroderma, rheumatoid arthritis, and inflammatory myositis.
Dr Maher is an associate editor for American Journal of Respiratory and Critical Care Medicine and is on the editorial board of Lancet Respiratory Medicine. He has authored over 270 papers and book chapters on pulmonary fibrosis.